Compugen ( (CGEN) ) has released its Q1 earnings. Here is a breakdown of the information Compugen presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Compugen Ltd. is a clinical-stage cancer immunotherapy company based in Israel, known for its pioneering work in computational target discovery and development of innovative cancer treatments. In its first quarter of 2025 earnings report, Compugen highlighted significant progress in its clinical trials and partnerships, alongside a stable financial position. The company initiated a trial for COM701 maintenance therapy for ovarian cancer and continued its Phase 1 trial for GS-0321, an anti-IL18BP antibody licensed to Gilead. Additionally, its partner AstraZeneca expanded the rilvegostomig program to ten Phase 3 trials, potentially enhancing Compugen’s future revenue streams. Financially, Compugen reported a slight decrease in revenue to $2.3 million compared to the previous year, with a net loss of $7.2 million. However, the company maintains a solid cash position expected to support operations until 2027. Looking ahead, Compugen is poised for growth with upcoming leadership changes and continued advancements in its clinical pipeline, leveraging its AI/ML-powered discovery platform.